NCT03424603: Phase 1: Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, B-Cell Malignancies

• NCT03424603: Phase 1: Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies

Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies

First-in-human Phase 1 trial to study the safety, pharmacokinetics and preliminary efficacy of STRO-001 given intravenously every 3 weeks.

Sponsor

Sutro Biopharma, Inc.

Multiple Locations

---

ClinicalTrials.gov Identifier: NCT03424603

Official Title: A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies

First Posted : February 7, 2018

Click here to see details on ClinicalTrials.gov

STRO-001-BCM1

---

Drug: STRO-001

intravenous antibody drug conjugate

Anti-CD74 Antibody-drug Conjugate STRO-001

Anti-CD74 Antibody-drug Conjugate STRO-001 (Code C148066)

ADC STRO-001

Anti-CD74 ADC STRO-001

Anti-CD74 Antibody-drug Conjugate STRO-001

SP7675

STRO-001

---

Locations

United States, Alabama

United States, Arizona

United States, California

United States, Colorado

United States, Georgia

United States, Indiana

United States, Kansas

United States, Maryland

United States, Michigan

United States, New York

United States, Oregon

United States, Texas

United States, Virginia

United States, West Virginia

United States, Wisconsin